A detailed history of Allspring Global Investments Holdings, LLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 79,822 shares of COLL stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,822
Previous 43,491 83.54%
Holding current value
$2.39 Million
Previous $1.4 Million 120.29%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$31.4 - $39.07 $1.14 Million - $1.42 Million
36,331 Added 83.54%
79,822 $3.08 Million
Q2 2024

Jul 26, 2024

SELL
$31.36 - $39.99 $61,057 - $77,860
-1,947 Reduced 4.28%
43,491 $1.4 Million
Q1 2024

Apr 18, 2024

SELL
$31.23 - $40.91 $13,241 - $17,345
-424 Reduced 0.92%
45,438 $1.76 Million
Q4 2023

Jan 25, 2024

BUY
$21.16 - $30.8 $88,702 - $129,113
4,192 Added 10.06%
45,862 $1.41 Million
Q3 2023

Oct 27, 2023

BUY
$21.23 - $24.28 $884,654 - $1.01 Million
41,670 New
41,670 $931,000
Q2 2023

Jul 18, 2023

BUY
$21.06 - $24.0 $24,892 - $28,368
1,182 Added 46.5%
3,724 $80,000
Q1 2023

Apr 13, 2023

BUY
$23.0 - $29.88 $13,363 - $17,360
581 Added 29.63%
2,542 $60,000
Q4 2022

Jan 23, 2023

SELL
$16.14 - $23.55 $694 - $1,012
-43 Reduced 2.15%
1,961 $0
Q3 2022

Oct 26, 2022

BUY
$15.46 - $20.1 $3,787 - $4,924
245 Added 13.93%
2,004 $32,000
Q2 2022

Jul 25, 2022

SELL
$14.22 - $20.88 $912,326 - $1.34 Million
-64,158 Reduced 97.33%
1,759 $31,000
Q1 2022

May 02, 2022

SELL
$17.2 - $22.5 $260,442 - $340,695
-15,142 Reduced 18.68%
65,917 $1.34 Million
Q4 2021

Jan 28, 2022

BUY
$17.5 - $21.35 $1.42 Million - $1.73 Million
81,059 New
81,059 $1.51 Million

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.02B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.